Publication | Closed Access

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Breast OncologyOncologyMedicineImmunologyAdvanced BreastBreast CancerImmunotherapeuticsAnti-cancer AgentTargeted TherapyCancer TreatmentAntitumour ActivityPharmacologyPhase 1